Dogwood Therapeutics, Inc. Income Tax Expense
Dogwood Therapeutics, Inc. (DWTX) reported Income Tax Expense of $221.10 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-18
- Dogwood Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $221.10K.
- Dogwood Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was -$503.00.
| Period end | Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $221.10K 10-K · filed 2026-03-18 |
| 2024-12-31 | -$503.00 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |